Internal Medicine
Latest news
324 articles · 20 / page
Minor Papillotomy for Pancreas Divisum: The SHARP Trial Challenges Decades of Endoscopic Practice
The SHARP randomized clinical trial finds that minor papillotomy does not significantly reduce the risk of recurrent acute pancreatitis in patients with pancreas divisum. These results challenge long-standing clinical practices and emphasiz
Beyond the Initial Quit: Mobile Chat Messaging as a Scalable Solution for Smoking Relapse Prevention
Recent clinical trials demonstrate that mobile chat-based interventions, combining live counselors and chatbots, significantly reduce smoking relapse rates and improve long-term abstinence through personalized, real-time support and engagem
Despite Free Devices and Personalized Support, One-Third of Patients Fail to Engage with Home Blood Pressure Monitoring
A retrospective cohort study of 3,390 patients reveals that 32.7% showed zero engagement with home blood pressure monitoring (HBPM) despite receiving free equipment and navigator support, highlighting significant behavioral and procedural b
Oral Nalbuphine Significantly Reduces Cough Frequency in Patients with Idiopathic Pulmonary Fibrosis: Results from the CORAL Trial
The CORAL Phase 2b trial demonstrates that oral nalbuphine extended release significantly reduces objective cough frequency and improves patient-reported symptoms in idiopathic pulmonary fibrosis, addressing a critical unmet need for managi
Beta-Cell Function, Not Glucagon, Predicts Glycemic Success: A Critical Analysis of the GRADE Study
A sub-analysis of the GRADE study reveals that beta-cell function (C-peptide index), rather than alpha-cell responses (glucagon), is the primary driver of glycemic durability in type 2 diabetes across various medication classes, suggesting
Challenging the Metformin Monopoly: Insights from the SMARTEST Trial on Early-Stage Type 2 Diabetes Management
The SMARTEST trial investigates whether dapagliflozin should replace metformin as first-line therapy for early type 2 diabetes. Baseline data reveals a surprisingly high microvascular event rate, highlighting the urgent need for early organ
Scaling the Notes: Feasibility Study Confirms Singing for Lung Health as a Viable Maintenance Strategy Post-Pulmonary Rehabilitation
A multicentre feasibility trial demonstrates that Singing for Lung Health (SLH) is a viable follow-up to pulmonary rehabilitation, showing high retention rates and strong participant enthusiasm for a definitive randomized controlled trial.
Rethinking Rhythm Management: Catheter Ablation Outperforms Medical Therapy in Atrial Fibrillation Patients with High Comorbidity Burden
A post hoc analysis of the CABANA trial reveals that catheter ablation significantly reduces major cardiovascular events and improves quality of life in AF patients with high comorbidity burden (≥4 conditions), suggesting that multimorbidit
Mediterranean Diet Outperforms Traditional Dietary Advice for Irritable Bowel Syndrome: A Landmark Randomized Trial
A randomized clinical trial published in the Annals of Internal Medicine reveals that the Mediterranean diet is superior to traditional dietary advice for managing IBS symptoms, offering a nutrient-dense, sustainable first-line intervention
Is 2 Liters of PEG Necessary? Simplified Water Prep Proves Effective for Crohn’s Capsule Endoscopy
A randomized trial demonstrates that a simplified bowel preparation using clear liquids and water offers comparable diagnostic yield and cleanliness to PEG-based regimens for Crohn’s disease capsule endoscopy, while significantly improving
Iptacopan Demonstrates Clinical Efficacy in Cold Agglutinin Disease While Falling Short in Immune Thrombocytopenia: Results from a Phase 2 Basket Trial
This Phase 2 basket trial highlights the divergent efficacy of the oral factor B inhibitor iptacopan, showing significant hemoglobin improvements in Cold Agglutinin Disease but failing to meet platelet response endpoints in Immune Thrombocy
NT-proBNP-Defined Heart Stress: A New Compass for Individualized Blood Pressure Targets in Older Adults?
A post hoc analysis of the ASPREE trial reveals that heart stress, measured by NT-proBNP, significantly alters the relationship between blood pressure and cardiovascular risk in older adults, suggesting a paradigm shift toward biomarker-gui
Survival Proportional Odds Outperforms Cox Regression in High-Heterogeneity Heart Failure Trials: Insights from DAPA-HF and DELIVER
A critical reanalysis of the DAPA-HF and DELIVER trials reveals that the survival proportional odds model provides greater statistical power and more robust treatment effect estimates than traditional Cox regression in heart failure populat
Precision Medicine in Atrial Fibrillation: Biomarker-Based ABC-AF Risk Scores Fail to Outperform Standard Care
A large-scale registry-based RCT reveals that tailoring atrial fibrillation treatment using the biomarker-driven ABC-AF risk score does not significantly reduce stroke or death compared to current standard guideline-based care, highlighting
Aspirin vs. Clopidogrel Beyond 30 Days Post-PCI: Equivalent Outcomes Regardless of Oral Anticoagulation Status
A subgroup analysis of the STOPDAPT-3 trial reveals that aspirin and clopidogrel offer similar cardiovascular protection and bleeding safety between 1 month and 1 year post-PCI, regardless of whether patients are also receiving oral anticoa
Targeted Education Enhances Rhythm Control Adherence in Atrial Fibrillation but Faces Limits in Stroke Prevention: Insights from STEEER-AF
The STEEER-AF cluster-randomized trial reveals that structured professional education significantly boosts adherence to complex rhythm control guidelines in atrial fibrillation, though it shows no significant impact on stroke prevention whe
Mavacamten Redefines Long-Term Outcomes in Obstructive Hypertrophic Cardiomyopathy: 128-Week Results From the VALOR-HCM Trial
The 128-week follow-up of the VALOR-HCM trial demonstrates that mavacamten provides sustained relief from LVOT obstruction, promotes favorable cardiac remodeling, and significantly reduces the need for invasive septal reduction therapy in p
Moving Beyond the 12-Month Default: Personalized DAPT Duration Proven Superior in the PARTHENOPE Trial
The PARTHENOPE randomized trial demonstrates that personalizing DAPT duration (3 to 24 months) based on individual risk scores significantly reduces net adverse clinical events compared to standard 12-month therapy, primarily by lowering is
Finerenone Provides Robust Protection Against Heart Failure Events Regardless of Baseline NYHA Functional Class
A prespecified analysis of the FINEARTS-HF trial confirms that finerenone reduces cardiovascular death and heart failure events in patients with HFmrEF and HFpEF across all symptomatic stages, offering the greatest absolute benefit to those
Intensive Blood Pressure Control to <120 mmHg: Holistic Benefits Across Frailty, Quality of Life, and Microvascular Health in the ESPRIT Trial
The ESPRIT trial reveals that targeting systolic blood pressure below 120 mmHg significantly reduces cardiovascular events across diverse populations, including frail patients and those with diabetes, while uniquely improving retinal microv
Browse by specialty
Open language-specific specialty feeds and department pages.